In the ACCELERATE study of 1309 patients with genotypes 2 and 3 who were randomized into 16 week and 24 week treatment groups, 66% 863 patients, 458 after 16 weeks and 405 after 24 weeks of the total study population reached rapid viral responses RVR.
En un análisis del estudio ACCELERATE que incluyo un total de 1309 pacientes con genotipo 2/3, un 66% 863 pacientes alcanzaron una respuesta viral rápida RVR y fueron aleatorizados a 16 semanas 458 vs. 24 semanas 405 de tratamiento.